Heron Therapeutics HRTX 深 沪
等待开盘 09-19 09:30:00 美东时间
1.29
+0.080
+6.61%
华盛通- 最 高1.30
- 今 开1.23
- 成交量 247.19万股
- 最 低 1.22
- 昨 收 1.21
- 总市值 1.97亿
- 52周最高 2.68
- 市盈率 静 --
- 换手率 1.62%
- 52周最低 1.04
- 委 比 -33.06%
- 总股本 1.53亿
- 历史最高 42.90
- 量 比 1.90
- 振 幅 6.61%
- 历史最低 0.16
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Heron Therapeutics Signs New Headquarters Lease
Heron Therapeutics ( ($HRTX) ) has shared an update. Heron Therapeutics, Inc. h...
08-29 05:30
HeartCore Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
HeartCore Enterprises Inc., a leading enterprise software and consulting services company, announced that it has regained compliance with the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. This determination was based on the company’s June 30, 2025, quarterly report, which reported stockholders’ equity of $3,559,017. HeartCore provides SaaS solutions, data analytics services, customer exp...
08-28 12:30
Heron Therapeutics Adopts Tax Benefit Preservation Plan
The latest announcement is out from Heron Therapeutics ( ($HRTX) ). On August 1...
08-15 20:24
Heron Therapeutics Signs Agreement with Patheon
An announcement from Heron Therapeutics ( ($HRTX) ) is now available. On August...
08-13 05:12
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.
08-09 03:01
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Heron Therapeutics shares are trading lower after the company reported worse-th...
08-08 20:57
Heron Therapeutics announces capital restructuring to support growth
Heron Therapeutics (NASDAQ:HRTX) Friday reported the completion of a comprehensive capital restructuring designed to enhance the company's financial flexibility, reduce total debt, and support long-te...
08-08 20:41
Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $158.538M Est
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $158.538 million estimate.
08-08 19:57
